Myovant Sciences Long Term Debt 2017-2022 | MYOV

Myovant Sciences long term debt from 2017 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Myovant Sciences Annual Long Term Debt
(Millions of US $)
2022 $359
2021 $359
2020 $114
2019 $93
2018 $44
2017 $
2016 $
Myovant Sciences Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $359
2022-03-31 $359
2021-12-31 $359
2021-09-30 $359
2021-06-30 $359
2021-03-31 $359
2020-12-31 $314
2020-09-30 $254
2020-06-30 $194
2020-03-31 $114
2019-12-31 $114
2019-09-30 $92
2019-06-30 $89
2019-03-31 $93
2018-12-31 $97
2018-09-30 $45
2018-06-30 $44
2018-03-31 $44
2017-12-31 $29
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.600B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00